1 Department of Medicinal Chemistry, Research Zakusov Institute of Pharmacology, Russia
2 Department of Pharmacogenetics, Research Zakusov Institute of Pharmacology, Russia
*Corresponding author: Tatiana A Gudasheva, Department of Medicinal Chemistry Research Zakusov, Institute of Pharmacology, Moscow, Russia
Submission: August 17, 2018; Published: October 01, 2018
ISSN : 2576-9170Volume2 Issue4
BDNF may represent a beneficial therapeutically agent against a variety of neurological and psychiatric disorders, but bad pharmacokinetics complicate its clinical use. This article focuses on the design and BDNF-like biological properties of low-molecular weight dimeric dipeptide mimetics of BDNF free of these disadvantages.
Keywords:BDNF; ГСБ-106; Dipeptide; Low-molecular weight mimetic; Neuroprotection; Antidepressant-like activity
Abbreviations: TrkB: Tropomyosine-related Kinase B; BDNF: Brain-Derived Nurotrophic Factor; PI3K/AKT: Phosphatidylinositol 3-kinase/Protein Kinase B; MAPK/ERK: Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase; MCAO: Middle Cerebral Artery Occlusion